Next Article in Journal
Response to: “Counterpoint Re: ‘Mammography Screening—Sticking to the Science’”
Previous Article in Journal
Stereotactic Ablative Radiotherapy with CyberKnife for Advanced Thymic Carcinoma: A Case Report
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 22
Issue 5
10.3747/co.22.2635
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Case Report

Imatinib for Highly Chemoresistant Kaposi Sarcoma in a Patient with Long-Term HIV Control: A Case Report and Literature Review

by
W. Cao
1,2,3,*,
K. Vyboh
1,2,
B. Routy
4,5,
M. Chababi-Atallah
6,
B. Lemire
1 and
J.P. Routy
1,2,7,*
1
Chronic Viral Illnesses Service, McGill University Health Centre, Montreal, QC, Canada
2
Research Institute, McGill University Health Centre, Montreal, QC, Canada
3
Department of Infectious Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China
4
de Cancérologie Gustave Roussy, Villejuif, France
5
Institut national de la santé et de la recherche médicale (inserm), Villejuif, France
6
Department of Pathology, Centre hospitalier universitaire de Sherbrooke, Sherbooke, QC, Canada
7
Division of Hematology and Chronic Viral Illness Service, McGill University Health Centre, Glen Site, 1001 Boulevard Décarie, EM 3-3232, Montreal, Quebec H4A 3J1, Canada
*
Authors to whom correspondence should be addressed.
Curr. Oncol. 2015, 22(5), 395-399; https://doi.org/10.3747/co.22.2635
Submission received: 9 July 2015 / Revised: 5 August 2015 / Accepted: 9 September 2015 / Published: 1 October 2015

Abstract

Kaposi sarcoma (ks) is a vascular tumour caused by oncogenic human herpesvirus type 8; it often occurs with hiv-associated immunosuppression. Numerous cellular signalling pathways are involved in the pathogenesis of ks, among which receptor tyrosine kinases such as the c-Kit and platelet-derived growth factor receptors play an important role. Imatinib mesylate, a tyrosine kinase inhibitor, has resulted in partial regression of ks lesions in one third of treated patients, but its mechanism of action remains unclear. Here, we report the case of a white man with recurrent ks despite well-suppressed hiv infection and multiple chemotherapies who received imatinib and showed a complete and sustained tumour response. To our knowledge, this report is the first showing the value of imatinib in the management of ks in the context of long-lasting hiv control with adequate quantitative CD4 recovery. Our case indicates that imatinib can be a treatment option for highly chemoresistant recurrent ks in patients on long-term antiretroviral therapy.
Keywords: hiv-1; Kaposi sarcoma; imatinib; autophagy hiv-1; Kaposi sarcoma; imatinib; autophagy

Share and Cite

MDPI and ACS Style

Cao, W.; Vyboh, K.; Routy, B.; Chababi-Atallah, M.; Lemire, B.; Routy, J.P. Imatinib for Highly Chemoresistant Kaposi Sarcoma in a Patient with Long-Term HIV Control: A Case Report and Literature Review. Curr. Oncol. 2015, 22, 395-399. https://doi.org/10.3747/co.22.2635

AMA Style

Cao W, Vyboh K, Routy B, Chababi-Atallah M, Lemire B, Routy JP. Imatinib for Highly Chemoresistant Kaposi Sarcoma in a Patient with Long-Term HIV Control: A Case Report and Literature Review. Current Oncology. 2015; 22(5):395-399. https://doi.org/10.3747/co.22.2635

Chicago/Turabian Style

Cao, W., K. Vyboh, B. Routy, M. Chababi-Atallah, B. Lemire, and J.P. Routy. 2015. "Imatinib for Highly Chemoresistant Kaposi Sarcoma in a Patient with Long-Term HIV Control: A Case Report and Literature Review" Current Oncology 22, no. 5: 395-399. https://doi.org/10.3747/co.22.2635

APA Style

Cao, W., Vyboh, K., Routy, B., Chababi-Atallah, M., Lemire, B., & Routy, J. P. (2015). Imatinib for Highly Chemoresistant Kaposi Sarcoma in a Patient with Long-Term HIV Control: A Case Report and Literature Review. Current Oncology, 22(5), 395-399. https://doi.org/10.3747/co.22.2635

Article Metrics

Back to TopTop